Brokerages forecast that United Therapeutics Corporation (NASDAQ:UTHR) will report sales of $430.87 million for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for United Therapeutics Corporation’s earnings. The lowest sales estimate is $415.90 million and the highest is $442.51 million. United Therapeutics Corporation posted sales of $408.20 million in the same quarter last year, which suggests a positive year over year growth rate of 5.6%. The firm is expected to report its next quarterly earnings results on Thursday, October 26th.

On average, analysts expect that United Therapeutics Corporation will report full year sales of $430.87 million for the current year, with estimates ranging from $1.59 billion to $1.72 billion. For the next fiscal year, analysts forecast that the business will report sales of $1.38 billion per share, with estimates ranging from $1.22 billion to $1.55 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover United Therapeutics Corporation.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the firm posted $4.42 earnings per share.

Several research analysts have recently issued reports on UTHR shares. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine upgraded shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. UBS AG reiterated a “sell” rating and issued a $106.00 price target on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Jefferies Group LLC reiterated a “sell” rating and issued a $105.00 price target on shares of United Therapeutics Corporation in a report on Thursday, June 8th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company’s stock. United Therapeutics Corporation has a consensus rating of “Hold” and a consensus price target of $134.50.

COPYRIGHT VIOLATION WARNING: “United Therapeutics Corporation (UTHR) Expected to Announce Quarterly Sales of $430.87 Million” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/10/united-therapeutics-corporation-uthr-expected-to-announce-quarterly-sales-of-430-87-million.html.

In other United Therapeutics Corporation news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Thursday, September 7th. The stock was sold at an average price of $134.48, for a total value of $77,998.40. Following the completion of the transaction, the director now owns 3,295 shares of the company’s stock, valued at approximately $443,111.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 1,234 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $132.32, for a total value of $163,282.88. Following the completion of the transaction, the chief executive officer now directly owns 1,374 shares of the company’s stock, valued at approximately $181,807.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,178 shares of company stock valued at $3,289,427. 7.80% of the stock is owned by insiders.

Institutional investors have recently added to or reduced their stakes in the business. Focused Wealth Management Inc grew its stake in shares of United Therapeutics Corporation by 17.5% during the 1st quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 140 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of United Therapeutics Corporation by 17.4% during the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 200 shares during the period. Campbell & CO Investment Adviser LLC bought a new position in shares of United Therapeutics Corporation during the 1st quarter valued at approximately $204,000. Eagle Global Advisors LLC bought a new position in shares of United Therapeutics Corporation during the 2nd quarter valued at approximately $206,000. Finally, Clarity Capital KCPS Ltd. bought a new position in shares of United Therapeutics Corporation during the 1st quarter valued at approximately $230,000.

United Therapeutics Corporation (NASDAQ UTHR) traded down 9.51% during midday trading on Friday, reaching $120.82. 2,279,211 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $130.10 and a 200-day moving average of $130.86. The stock has a market cap of $5.25 billion, a PE ratio of 14.01 and a beta of 1.52. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics Corporation (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.